J&J May Look Elsewhere

Johnson & Johnson (JNJ) must be one of luckiest companies around. They were inches away from a rotten deal that got worse each day. It featured Guidant threatening to sue them unless J&J bought them out. Then after that, the two would have to work together.
Well, it looks like Boston Scientific (BSX) is serious. They’re really going after Guidant (GDT). Of course, the deal will crush them, but I’ll give them points for bravery. The AP noted that the deal would cut BSX’s short-term earnings and quadruple their debt. Outside that, it’s a great deal! Oh, and the huge legal problems.
Johnson & Johnson (JNJ) released a statement saying that they believe the current offer “represents full and fair value.” BA! You gotta love putting out a statement like that. It’s one of the few times you can tell people to go to hell and sound conciliatory at the same time. I’m sure it got plently of laughs at the office.
Now what does J&J do? I definitely think they’re still game for a merger, and that leads them right to our Buy List. The most obvious purchase would be Medtronic (MDT), but they’re too big even for J&J. In fact, MDT could jump in and make a bid for Guidant. However, looking at Guidant’s price, I don’t think we’ll see anymore offers.
A good idea for J&J would be to go after Varian (VAR), but I think the company wants to stay independent. With Guidant out of the way, the only company left that solely focuses on pacemakers and implantable defibrillators is St. Jude Medical (STJ). In every way, I think it’s a better deal for Johnson & Johnson. The only problem is that STJ is up 7.2% in the last six trading sessions. Which has been good news for us!

Posted by on December 8th, 2005 at 10:14 am


The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment. I or my affiliates may hold positions or other interests in securities mentioned in the Blog, please see my Disclaimer page for my full disclaimer.